Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

225 results about "Isoxazole" patented technology

Isoxazole is an azole with an oxygen atom next to the nitrogen. It is also the class of compounds containing this ring. Isoxazolyl is the univalent radical derived from isoxazole.

Lithium ion battery and electric equipment

The invention belongs to the technical field of secondary batteries, and particularly relates to a lithium ion battery and electric equipment. The lithium ion battery provided by the invention comprises a positive plate, a negative plate and an electrolyte, the electrolyte comprises an isoxazole compound, and based on the total mass of the electrolyte, the mass percentage A% of the isoxazole compound is 1-40%; the negative plate comprises a negative electrode active material layer containing a negative electrode active material, the negative electrode active material comprises a carbon-based material and a silicon-carbon material, and based on the total mass of the negative electrode active material layer, the mass percentage B% of the silicon-carbon material is 1.5-80%. By limiting the content of the isoxazole compound in the electrolyte and the content of the silicon-carbon material in the negative electrode active material, a stable SEI film can be formed while the energy density is improved, expansion is inhibited, and the cycle performance is improved.
Owner:ZHUHAI COSMX BATTERY CO LTD

Environment-friendly flame-retardant polyester yarn and preparation method thereof

The invention discloses an environment-friendly flame-retardant polyester yarn and a preparation method thereof, and relates to the technical field of textile, and the environment-friendly flame-retardant polyester yarn is prepared from the following raw materials in parts by weight: 100 parts of polyester chips, 10-15 parts of a flame-retardant polymer containing an organic salt structure, 1-3 parts of an antioxidant, 0.8-2 parts of a lubricant, 1-2 parts of benzotriazole sodium and 0.8-1.2 parts of quinoline yellow. The flame-retardant polymer containing the organic salt structure comprises a structural unit introduced by the following monomers: bis (3-aminophenyl) (3, 5-bis (trifluoromethyl) phenyl) phosphine oxide, 3, 7-diamino-5-phenylphenazine chloride and 3, 5-isoxazole dicarboxylic acid. The environment-friendly flame-retardant polyester yarn is good in ultraviolet aging resistance and flame retardance, high in strength and sufficient in softness.
Owner:YANGZHOU LEKANG TEXTILE TECH CO LTD

Isoxazole-3-carboxyamide compounds for enhancing telomerase reverse transcriptase (TERT) expression

Telomerase reverse transcriptase (TERT) expression enhancing isoxazole-3-carboxamide compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.
Owner:SIERRA SCIENCES LLC

Use of isoxazolinecarboxamide for sprout inhibition

The invention relates to the field of food storage, more specifically to the use of methyl(2R*,4R*)-4-[[(5S)-3-(3,5-difluorophenyl)-5-vinyl-4H-isoxazole-5-carbonyl]amino]tetrahydrofuran-2-carboxy-late (I) for sprout inhibition in crops, the use of combinations or compositions comprising thereof for sprout inhibition in crops and a method for controlling sprouts on crops.
Owner:BAYER AG

Sulfonamide compound, pharmaceutical composition and application thereof

The invention relates to a sulfonyl compound and a pharmaceutical composition and application thereof. The sulfonamide compound comprises a compound as shown in formula I: # imgabs0 #. The sulfonamide compound has a benzyne structure located on the left side of sulfonyl and a pyridino isoxazole structure located on the right side of sulfonyl. Through the synergistic effect of sulfonyl, a benzyne structure and a pyridoisoxazole structure, the druggability of the compound and the capability of competitively combining with acetyl coenzyme to KAT6A / KAT6B can be remarkably improved, the acetyl coenzyme is inhibited from combining with KAT6A / KAT6B to catalyze histone related sites, and gene expression inducing cancer cell growth is prevented; further, the KAT6A / KAT6B gene can be used for treating related tumor diseases caused by KAT6A / KAT6B gene amplification or KAT6A / KAT6B protein overexpression.
Owner:BEIJING KONRUNS PHARM CO LTD

Preparation method and application of Co and N loaded Ti3AlC2 composite catalyst

The invention relates to the technical field of organic pollutant removal application, and particularly discloses a preparation method and application of a Co and N loaded Ti3Al C2 composite catalyst, and the preparation method comprises the step of successfully doping N and Co into the surface of Ti3Al C2 to synthesize a Co-N-Ti3Al C2 composite material by adopting a simple hydrothermal combined high-temperature carbonization method. Compared with a double combination of the materials, the Co-N-Ti3Al C2 has higher PMS activation and sulfonamide isoxazole (S IZ) degradation capability, and 98.6% of S IZ simulation wastewater with the concentration of 10 mg / L can be removed within 30 minutes by combining the Co-N-Ti3Al C2 with a PMS system. The high catalytic activity of the material is attributed to the strong interaction between pyridine N and Co atoms on the surface of Ti3AlC2, and meanwhile, the strong interaction is also beneficial for inhibiting leaching of Co ions in the material. The Co-N-Ti3Al C2 composite material has the advantages that the Co-N-Ti3Al C2 composite material is high in interference resistance, high in activity in natural water and high in practical applicability.
Owner:CHIZHOU UNIV

Deep-sea pressure-resistant shell protective coating and preparation method thereof

The invention relates to the technical field of coatings, and discloses a deep-sea pressure-resistant shell protective coating and a preparation method thereof.The preparation method comprises the following steps that a base material is treated, epoxy resin modified polyurethane, reinforcing filler, anti-corrosion filler, a curing agent and a solvent are sequentially added according to a preset proportion and mixed to be uniform, primer is prepared, and the base material is sprayed with the primer; and then taking the isoxazole modified polyurea as finish paint, and spraying the finish paint on one side, deviating from the base material, of the primer to obtain the protective coating. The protective coating has excellent waterproof performance, impact resistance, wear resistance and organism adhesion resistance, and can effectively prevent corrosion factors such as moisture and various ions in seawater and various fouling organisms such as barnacles, mussels, oysters and sponges in seawater from being in contact with the surface of a base material.
Owner:湖北航聚科技股份有限公司

A protective coating for deep-sea pressure hull and its preparation method

This invention relates to the field of coating technology, and discloses a deep-sea pressure-resistant hull protective coating and its preparation method, comprising the following steps: substrate treatment, sequentially adding epoxy resin-modified polyurethane, reinforcing filler, anti-corrosion filler, curing agent and solvent in a predetermined proportion and mixing evenly to obtain a primer, and spraying the primer onto the substrate; then using isoxazole-modified polyurea as a topcoat, spraying the topcoat on the side of the primer away from the substrate to obtain the protective coating. This protective coating has excellent waterproof performance, impact resistance, wear resistance and anti-bioadhesion ability, and can effectively prevent water, various corrosive factors such as ions in seawater, and various polluting organisms in seawater such as barnacles, mussels, oysters and sponges from contacting the substrate surface.
Owner:湖北航聚科技股份有限公司

Synthetic method of isoxazole compound under visible light catalysis condition

PendingCN121974865AOrganic chemistryOrganic synthesisN-butyl nitrite
The invention belongs to the technical field of organic synthesis, and particularly relates to a synthesis method of an isoxazole compound under a visible light catalysis condition. The method comprises the following steps: dissolving a compound 1 in 1, 2-dichloroethane, then adding tert-butyl nitrite, tribromomethane, alkali and a photocatalyst, in an inert gas environment, irradiating with visible light and stirring at room temperature to react, after the reaction is completed, reducing pressure to remove a solvent, and then performing silica gel column purification on a crude product to obtain a product, namely the isoxazole compound. The brand-new method for preparing the isoxazole compound through visible light catalysis is developed, the conditions of high temperature and high pressure in a traditional synthesis method are avoided, energy consumption and environmental pollution are remarkably reduced, and the yield of the isoxazole compound is effectively increased by regulating and controlling reaction conditions and optimizing raw material selection and proportion.
Owner:GUANGDONG UNIV OF PETROCHEMICAL TECH

Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds

This disclosure provides a chemically modified induced pluripotent stem (iPS) cell derived from parental cells and methods for generating the chemically induced pluripotent stem (iPS) cells, as well as cardiac progenitor cells capable of producing cells of multiple sub-lineages. The iPS cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue or to rejuvenating cardiac muscles in a patient in need thereof and to treat cardiac disease.
Owner:IPS HEART

Metal peroxide complex molecular catalyst, preparation method and application thereof, and continuous synthesis method of pyroxasulfone

The invention provides a metal peroxide complex molecular catalyst, a preparation method and application thereof, and a continuous synthesis method of pyroxasulfone. A transition metal ion center, an organic ligand, a metal-peroxide bridged bond (M-O-O-M) and other structures are introduced into the prepared metal peroxide complex molecular catalyst, and under the synergistic effect of the structures, the prepared metal peroxide complex molecular catalyst is used for oxidizing thioether into sulfone. The catalyst has excellent selectivity and catalytic efficiency. Particularly, when the catalyst is used for catalyzing 3-[(5-difluoromethoxy-1-methyl-3-trifluoromethylpyrazole-4-yl)-methylthio]-4, 5-dihydro-5, 5-dimethyl-1, 2-isoxazole to be oxidized and synthesized into pyroxasulfone, the reaction efficiency, selectivity and safety of the oxidation reaction can be effectively improved, and therefore the preparation cost of pyroxasulfone can be further reduced advantageously, and the catalyst can be used for catalyzing 3-[(5-difluoromethoxy-1-methyl-3-trifluoromethylpyrazole-4-yl)-methylthio]-4, 5-dihydro-5, 5-dimethyl-1, 2-isoxazole to be oxidized and synthesized into pyroxasulfone.
Owner:TIANJIN ASYMCHEM MEDICAL SCI & TECH DEV CO LTD

Method for simply and conveniently preparing high-purity lotinib

The invention relates to a method for simply and conveniently preparing high-purity lotinia, which comprises the following steps of: reacting 5-acetyl-3-methyl-2-thiophenecarboxylic acid with 2, 2, 2-trifluoro-1-trichlorophenyl ethyl-1-ketone to obtain 3-methyl-5-(4, 4, 4-trifluoro-3-trichlorophenyl butyl-2-enoyl) thiophene-2-formic acid, and reacting the 3-methyl-5-(4, 4, 4-trifluoro-3-trichlorophenyl butyl-2-enoyl) thiophene-2-formic acid with 2, 2, 2-trifluoro-1-trichlorophenyl ethyl-1-ketone to obtain 3-methyl-5-(4, 4, 4-trifluoro-3-trichlorophenyl butyl-2-enoyl) thiophene-2-carboxylic acid. Reacting the isoxazole thiophene formic acid compound with hydroxylamine hydrochloride to obtain an isoxazole thiophene formic acid compound; the preparation method comprises the following steps: reacting 5-[(5S)-5-trichlorophenyl-5-trifluoromethyl-4, 5-dihydro-isoxazole-3-yl]-3-methyl-thiophene-2-formic acid with (R)-1-(p-tolyl) ethyl-1-amine to obtain 5-[(5S)-5-trichlorophenyl-5-trifluoromethyl-4, 5-dihydro-isoxazole-3-yl]-3-methyl-thiophene-2-formic acid; and finally, carrying out condensation on the product and 2-amino-N-trifluoroethyl acetamide hydrochloride, so as to obtain the (5S)-configuration final product lotinib. The method has the advantages of short synthetic route, simple process, mild reaction and high chiral purity and HPLC purity, and is especially suitable for large-scale production.
Owner:北京元延医药科技股份有限公司

Medicinal salt of 3, 4-dihydro-2H-chromene [8, 7-d] isoxazole derivative and crystal form thereof

The present disclosure relates to a pharmaceutically acceptable salt of a 3, 4-dihydro-2H-chromene [8, 7-d] isoxazole derivative, and a crystalline form thereof. Specifically, the invention provides a pharmaceutically acceptable salt of N-(5-((1H-pyrazol-1-yl) methyl)-3, 4-dihydro-2H-chromene [8, 7-d] isoxazol-9-yl)-2-methoxybenzenesulfonamide, a crystal form and a preparation method thereof, and the corresponding salt has good stability and can be better used for clinical treatment.
Owner:SHANDONG SUNCADIA MEDICINE CO LTD

Isoxazole carboxylic acids as LPA antagonists

The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
Owner:BRISTOL MYERS SQUIBB CO

Self-repairing mute tire and preparation method thereof

The invention discloses a self-repairing mute tire and a preparation method thereof, and relates to the technical field of tires, the self-repairing mute tire comprises a tire body, and a self-repairing rubber layer and a mute material which are sequentially attached to the inner wall of the tire body from inside to outside; the self-repairing adhesive layer is prepared from the following components: epichlorohydrin rubber, acrylate rubber, a rosinyl phenyl phosphine oxide isoxazolyl functional polymer, 4, 4-chloroformyl phenyl ether, a catalyst, 2, 2-bis [4-(4-aminophenoxy) phenyl]-1, 1, 1, 3, 3, 3-hexafluoropropane, trithiocyanuric acid, a filler, an accelerant TMTD (Tetramethylthiuram Disulfide) and an auxiliary agent; the rosinyl phenyl phosphine oxide isoxazolyl functional polymer comprises structural units introduced through a condensation polymerization reaction of the following monomers: glycerol triabietate, bis (4-carboxyl phenyl) phenyl phosphine oxide and 3, 5-isoxazoledicarboxylic acid. The tire is remarkable in self-repairing effect, good in mute performance, sufficient in performance stability and long in service life.
Owner:WUXI I REACH TECH

(cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
Owner:CENTREXION THERAPEUTICS CORP

Use of isoxazolinecarboxamide for selective weed control in pineapple

PCT designated stageWO2025168777A1BiocideAnimal repellantsPineapple PlantCarboxylic acid
The invention relates to the field of crop protection, more specifically to the use of methyl (2R*,4R*)-4-[[(5S)-3-(3,5-difluorophenyl)-5-vinyl-4H-isoxazole-5-carbonyl]amino]tetrahydrofuran-2-carboxylate (I) and / or a salt thereof for control of undesired vegetation in an area comprising pineapple plants by an application over the top of the pineapple plants.
Owner:BAYER AG

Isoxazoline hybridized neolignan compound as well as preparation method and application thereof

The invention discloses an isoxazoline hybridized neolignan compound as well as a preparation method and application of the isoxazoline hybridized neolignan compound. The neolignan compound disclosed by the invention is one of isoxazoline magnolol, isoxazoline honokiol, isoxazoline nitrated magnolol and isoxazoline nitrated honokiol derivatives, and has the following chemical general formula: # imgabs0. The neolignan compound disclosed by the invention takes one of magnolol, honokiol, nitrated magnolol or nitrated mangnolia officinalis as a raw material; the preparation method comprises the following steps: by taking triethylamine as alkali and dichloromethane as a solvent, carrying out 1, 3-dipolar cycloaddition reaction on a raw material and alpha-chlorooxime, and separating and purifying to obtain the isoxazoline hybridized neolignan compound. The compound disclosed by the invention has relatively good insecticidal activity on plutella xylostella Linnaeus and Mythimna separata Walker, can be used for preparing a novel efficient insecticide, and is applied to prevention and treatment on the plutella xylostella Linnaeus and the Mythimna separata Walker.
Owner:SHANXI AGRI UNIV

Application of substituted isoxazole-5-ketone derivative

The invention provides application of a substituted isoxazole-5-ketone derivative, and belongs to the field of biological medicine. The invention finds that the compound as shown in the formula I is a high-activity inhibitor of human TyrRs enzyme for the first time, can be used for treating and / or preventing cancers and treating and / or preventing neurodegenerative diseases, provides a new choice for development of human TyrRs enzyme inhibitors and anti-aging and DNA repair drugs, and has a very good application prospect. # imgabs0 #
Owner:PEOPLES HOSPITAL OF HENAN PROV

Crystalline forms of the CXCR7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-YL-cyclopropyl)-amide

The application relates to crystalline forms of (3S,4S)-1- Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3- carbonyl]- amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclo- propyl)- amide; processes for the preparation thereof, and pharmaceutical compositions containing such crystalline forms. The compound acts as CX- CR7 receptor modulator and is thus useful for the treatment of cancer.
Owner:IDORSIA PHARMACEUTICALS LTD

Continuous synthesis method of 5-(2, 4-difluorophenyl) isoxazole-3-ethyl formate

The invention relates to a continuous synthesis method of ethyl 5-(2, 4-difluorophenyl) isoxazole-3-formate. The preparation method comprises the following steps: taking ethyl 4-(2, 4-difluorophenyl)-2, 4-dioxobutyrate and hydroxylamine hydrochloride as raw materials, uniformly mixing the materials through a micro mixer, and carrying out temperature control reaction in a heating delay tube to generate an intermediate solution; and introducing the intermediate solution into a dynamic tubular reactor, quenching with ultrapure water, aging to generate a solid-containing product mixed solution, concentrating, filtering, washing, drying and purifying to obtain the product. The 5-(2, 4-difluorophenyl) isoxazole-3-ethyl formate is continuously synthesized by utilizing the characteristics of enhanced mixing and reaction of the micro-mixer and the dynamic tubular reactor, the process is simple, the reaction time is short, the requirement on equipment temperature control is lower, the batch stability of the product can be ensured, and the product quality is improved.
Owner:SHENZHEN ZHIWEITONG TECH CO LTD

Isoxazole derivatives, their preparation methods, and their uses as drugs

The present invention relates to a novel isoxazole FXR agonist represented by general formula (I), a preparation method thereof, and a pharmaceutical composition containing the derivative for use in preparing a drug for preventing or / and treating FXR-related diseases. The isoxazole derivative has excellent FXR agonist activity and safety, and has broad application prospects. #imgabs0#
Owner:GUANGDONG PHARMA UNIV

Method for simultaneously enriching disordered protein and combining three-dimensional genome structure

The invention provides a method for simultaneously enriching disordered protein and a combined three-dimensional genome structure thereof, and relates to the technical field of molecular biology. The method comprises the following steps: after cross-linking cells with formaldehyde and disuccinimide glutaric acid (DSG), carrying out enzyme digestion treatment, terminal repair and adjacent connection by using restriction enzyme Dpn II; after connection, ultrasonically breaking the cell nucleus to obtain an ultrasonically broken product, dividing the ultrasonically broken product into two parts, capturing DNA and a protein complex of one part of the product by using biotinylated isoxazole, digesting protein by using protease, extracting and purifying the DNA, and carrying out library building and sequencing on the purified DNA; the other part of the product is treated by nuclease, protein is extracted, and then protein spectrum analysis is carried out. The method can realize whole genome non-destructive detection of the disordered protein and the three-dimensional structure of the chromatin combined with the disordered protein, and provides an effective way for structural analysis of the disordered protein.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

A process for preparation of isoxazole compound

The present invention relates to a novel process for preparation of an isoxazole compound of formula (I) by reacting a compound of formula (II) with a compound of formula (III). wherein, n is 0, 1 or 2; 10 R1, R2, R3 and R4 are independently hydrogen. C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; and R is linear or branched C1-6 alkyl group
Owner:UPL LTD

Isoxazole O-linked carbamoylcyclohexyl acids as LPA antagonists

The present invention provides a compound of formula (Ia) or (Ib) or a stereoisomer, tautomer or pharmaceutically acceptable salt or solvate thereof, wherein X 1 , X 2 , X 3 and X 4 Each independently is CR 6 or N; its premise is X 1 , X 2 , X 3 or X 4 No more than two of them are N; L is 0 to 4 R 7 Substituted C 1‑4 Alkylene; R 1 (‑CH 2 ) a R 9 ; a is an integer 0 or 1; R 2 are independently halogen, cyano, hydroxyl, amino, C 1‑6 Alkyl, C 3‑6 Cycloalkyl, C 4‑6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl or haloalkoxy; n is an integer of 0, 1 or 2; R 3 For hydrogen, C 1‑6 Alkyl, C 1‑6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy or haloalkoxy, and the alkyl itself or as part of other moieties is optionally partially or fully substituted with deuterium; R 4 C 1‑10 Alkyl, C 1‑10 Deuterated alkyl, C 1‑10 Haloalkyl, C 1‑10 Alkenyl, C 3‑8 Cycloalkyl, 6- to 10-membered aryl, 3- to 8-membered heterocyclic group, -(C 1‑6 Alkylene)‑(C 3‑8 Cycloalkyl), -(C 1‑6 alkylene)-(6 to 10 membered aryl),-(C 1‑6 alkylene)-(3 to 8 membered heterocyclic group) or-(C 1‑6 wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, aryl, heterocyclyl and heteroaryl groups is independently substituted by 0 to 3 R 8 Replace; or, R 3 and R 4 Together with the N atom to which it is attached, it forms a 8 Substituted 4 to 9 membered heterocyclic moiety; R 5 and R 6are independently hydrogen, halogen, cyano, hydroxyl, amino, C 1‑6 Alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy or haloalkoxy; R 7 is halogen, oxo, cyano, hydroxyl, amino, C 1‑6 Alkyl, C 3‑6 Cycloalkyl, C 4‑6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy or haloalkoxy; R 8 are independently deuterium, halogen, hydroxyl, amino, cyano, C 1‑6 Alkyl, C 1‑6 Deuterated alkyl, C 2‑6 Alkenyl, C 2‑6 alkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5- to 6-membered heteroaryl; or, two R 8 Together with the atoms to which they are attached, they form a 3- to 6-membered carbocyclic ring or a 3- to 6-membered heterocyclic ring, each of which is independently substituted by 0 to 3 R 12 Replacement; R 9 Selected from ‑CN, ‑C(O)OR 10 ,‑C(O)NR 11a R 11b , ‑CO‑NH‑CO‑R e , ‑CO‑NH‑SO 2 ‑R e , ‑CO‑NH‑SO‑R e ,‑SO 2 ‑OH, ‑SO 2 NH-CO-R e , ‑P(O)(OH) 2 , tetrazol-5-yl, -CH 2 ‑CO‑NH‑CO‑R e ,‑CH 2 ‑CO‑NH‑SO 2 ‑R e , CH 2 ‑CO‑NH‑SO‑R e ,‑CH 2 ‑SO 2 ‑OH, ‑CH 2 ‑SO 2 NH-CO-R e ,‑CH 2 ‑P(O)(OH) 2 , tetrazol-5-ylmethylene, R e C 1‑6 Alkyl, C 3‑6Cycloalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl or haloalkoxyalkyl; R 10 is hydrogen or C 1‑10 Alkyl; and R 11a and R 11b are independently hydrogen, C 1‑6 Alkyl, C 3‑6 Cycloalkyl, C 4‑6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy or haloalkoxy; and R 12 For halogen, cyano, hydroxyl, amino, C 1‑6 Alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl or 5- to 6-membered heteroaryl. These compounds are selective LPA receptor inhibitors. #imgabs0#
Owner:BRISTOL MYERS SQUIBB CO

A dihydrobenzofuranyl-containing isoxazole compound and its preparation method and application

The present invention discloses a dihydrobenzofuranyl-containing isoxazole compound, a preparation method thereof, and an application thereof. The dihydrobenzofuranyl-containing isoxazole compound is shown in formula (I). The compound or its pharmaceutically acceptable salt has a simple preparation method, high yield, and low cost. The obtained 3-(7-methoxy-2,3-dihydrobenzofuran-5-yl)-5-aryl isoxazole compound or its pharmaceutically acceptable salt exhibits high activity against plant pathogens such as cucumber downy mildew, has good control effects, and can be used as an alternative drug for plant fungicides.
Owner:HEBEI UNIVERSITY

Alpha-D-galactopyranoside derivatives

The present invention relates to compounds of Formula (I) wherein Ar1, R1 and R2 are as described in the description, and A is 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-1,3-diyl, oxazol-2-one-3,5-diyl and oxazolidine-2-one-3,5-diyl, 1,2,3-triazole-1,4-diyl, isoxazole-3,5-diyl, imidazole-1, 4-diyl, and isothiazole-3,5-diyl; and their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.
Owner:IDORSIA PHARMACEUTICALS LTD